Sihombing Unedo Hence Markus, Purwoto Gatot, Gandamihardja Supriadi, Harahap Alida R, Rustamadji Primariadewi, Kekalih Aria, Widyawati Retno, Fuady Dzicky Rifqi
Gynecologic-Oncology Division, Department of Obstetrics and Gynecology, Tarakan Hospital, Jakarta, Indonesia.
Gynecologic-Oncology Division, Department of Obstetrics and Gynecology, Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
Gynecol Oncol Rep. 2022 Jun 3;42:101005. doi: 10.1016/j.gore.2022.101005. eCollection 2022 Aug.
Ovarian cancer is the 8th deadliest common cancer in women around the world. Almost all ovarian cancer patients would experience chemoresistance, recurrence, and poor prognosis after cytoreductive surgery and platinum-based chemotherapy. Chemoresistant cancer cells have characteristic expressions of cancer stem cell proteins (CSCs) CD44/CD24, RAD6 and DDB2. The increased expression of CD44/CD24, RAD6, and decreased DDB2 are believed to be associated with chemoresistance, recurrence, and poor prognosis of the disease. Thus, this study's objective is to analyze the correlation between the expression of CD44/CD24, RAD6 and DDB2 with ovarian cancer chemoresistance.
This study was conducted with a prospective cohort of 64 patients who is divided into two groups (32 patients in each group) at the Obstetrics-gynecology and pathology department of Cipto Mangunkusumo, Tarakan, Dharmais, and Fatmawati Hospital. All suspected ovarian cancer patients underwent cytoreductive debulking and histopathological examination. Chemotherapy was given for six series followed by six months of observation. After the observation, we determined the therapy's response with the RECIST Criteria (Response Criteria in Solid Tumors) and then classified the results into chemoresistant or chemosensitive groups. Flow cytometry blood tests were then performed to examine the expression of CD44/CD24, RAD6 and DDB2.
There was a significant relationship between increased levels of CD44/CD24 and RAD6 (p < 0.05) levels with the chemoresistance of ovarian cancer. The logistic regression test showed that the CD44/CD24 was better marker.
These results indicate that CD44/CD24 and RAD6 expressions are significantly associated with ovarian cancer chemoresistance, and CD44/CD24 is the better marker to predict ovarian cancer chemoresistance.
卵巢癌是全球女性中致死率排名第8的常见癌症。几乎所有卵巢癌患者在减瘤手术和铂类化疗后都会出现化疗耐药、复发以及预后不良的情况。化疗耐药癌细胞具有癌症干细胞蛋白（CSCs）CD44/CD24、RAD6和DDB2的特征性表达。CD44/CD24、RAD6表达增加以及DDB2表达降低被认为与该疾病的化疗耐药、复发和预后不良有关。因此，本研究的目的是分析CD44/CD24、RAD6和DDB2的表达与卵巢癌化疗耐药之间的相关性。
本研究在西爪哇省芝多阿佐、打拉根、达玛伊斯和法玛瓦蒂医院的妇产科和病理科对64例患者进行前瞻性队列研究，将其分为两组（每组32例患者）。所有疑似卵巢癌患者均接受了减瘤手术和组织病理学检查。给予六个疗程的化疗，随后进行六个月的观察。观察结束后，我们根据实体瘤疗效评价标准（RECIST）确定治疗反应，然后将结果分为化疗耐药或化疗敏感组。然后进行流式细胞术血液检测，以检测CD44/CD24、RAD6和DDB2的表达。
CD44/CD24和RADb水平升高与卵巢癌化疗耐药之间存在显著关系（p<0.05）。逻辑回归检验表明，CD44/CD24是更好的标志物。
这些结果表明，CD44/CD24和RAD6的表达与卵巢癌化疗耐药显著相关，并且CD44/CD24是预测卵巢癌化疗耐药的更好标志物。
需注意，原文中“RADb”疑似有误，结合上下文推测可能是“RAD6”，译文按此推测翻译。
